And we estimate approval of ImmunoPulse for the treatment of melanoma may be obtained as early as in late 2017 if the pivotal trial data prove to be positive.
Does this seem late to anyone else? I'm a biotech newb, but Pierce has stated a couple of times he doesn't think a P3 will be needed. Wouldn't that change the timeline to late 2015 or 2016?